Welcome to our dedicated page for Disc Medicine news (Ticker: IRON), a resource for investors and traders seeking the latest updates and insights on Disc Medicine stock.
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. News about Disc Medicine frequently centers on its investigational pipeline, which targets fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Coverage of IRON often highlights regulatory and clinical milestones for bitopertin, DISC-0974, and DISC-3405. The company has reported submitting a New Drug Application for bitopertin in erythropoietic protoporphyria under the FDA’s accelerated approval pathway and receiving a Commissioner’s National Priority Voucher, a program designed to shorten review times for certain drugs. Updates also include progress in the APOLLO confirmatory trial of bitopertin.
Disc Medicine news also features data readouts and conference presentations. For DISC-0974, the company has reported initial Phase 2 results in anemia of myelofibrosis, describing substantial reductions in hepcidin, increases in iron, and positive effects on measures of anemia, as well as participation in major hematology meetings. For DISC-3405, Disc has announced Phase 2 and Phase 1b studies in polycythemia vera and sickle cell disease and has shared trial design information at scientific conferences.
Investors following IRON news will also see announcements related to public offerings of common stock and pre-funded warrants, updates on cash position and financial results, and corporate developments such as board changes, leadership appointments, and participation in investor and healthcare conferences. This combination of clinical, regulatory, financial, and corporate updates provides context for understanding Disc Medicine’s development-stage profile and strategic priorities.
Disc Medicine (NASDAQ:IRON) has announced multiple presentations at the upcoming 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentations include complete data from the Phase 1b trial of DISC-0974 in anemia of myelofibrosis and updates across their portfolio. The company will present clinical updates on core development programs in EPP, MF, and polycythemia vera, along with translational data from preclinical studies in new indications such as anemia of inflammatory bowel disease and sickle cell disease. Management will host a conference call on December 8 to review the presented data and discuss development plans.
Disc Medicine (NASDAQ:IRON) announced positive feedback from its end-of-Phase 2 meeting with the FDA regarding bitopertin for Erythropoietic Protoporphyria (EPP) treatment. The FDA agreed with all proposed study parameters for the APOLLO trial, including a primary endpoint measuring average monthly sunlight time without pain after 6 months of treatment. The company received potential for accelerated approval using PPIX reduction as a surrogate endpoint. The APOLLO trial, planned for mid-2025, will be a randomized, double-blind, placebo-controlled study using a 60 mg dose of bitopertin in EPP and XLP patients aged 12 and older.
Disc Medicine (NASDAQ:IRON) announced it will host a conference call on November 4, 2024, at 8:00 am EST to discuss feedback from its end-of-Phase 2 meeting with the FDA regarding bitopertin for Erythropoietic Protoporphyria (EPP). The company, which focuses on developing treatments for serious hematologic diseases, will make the call available through registration on their investor relations website.
Disc Medicine (NASDAQ:IRON) presented positive Phase 1b trial data for DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia. The single ascending dose (SAD) study included 40mg and 60mg cohorts, demonstrating that a single dose effectively suppressed hepcidin and increased iron mobilization, erythropoiesis, and hemoglobin levels. Key results showed >75% hepcidin reduction at the highest dose level, up to 3x increase in transferrin saturation, and mean hemoglobin increases of +0.54 g/dL at 40mg and +0.55 g/dL at 60mg compared to placebo. The treatment demonstrated acceptable safety with only Grade 1 or 2 related adverse events.
Disc Medicine (NASDAQ:IRON) has appointed Dr. Rahul Rajan Kaushik as Chief Technical Officer. Dr. Kaushik brings over 21 years of pharmaceutical development experience, specializing in Chemistry, Manufacturing, and Controls (CMC). He previously served as Senior VP of Technical Operations at FibroGen and held leadership positions at Nektar Therapeutics and Amgen. His experience includes successful development and regulatory approvals for multiple commercial products including Repatha®, Amgevita®, and contributions to Kyprolis®, Neulasta®, and Imlygic®. As part of his appointment, Disc granted Dr. Kaushik an inducement equity award including options for 55,000 shares and 36,666 restricted stock units.
Disc Medicine (NASDAQ:IRON) announced upcoming clinical data presentation at the 2024 American Society of Nephrology (ASN) Kidney Week, October 24-27, 2024, in San Diego. The presentation will feature additional data from Phase 1b trial of DISC-0974 in patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia.
The poster will report on 40mg and 60mg dose cohorts, focusing on safety, pharmacokinetics, and effects of DISC-0974 on hepcidin, iron, and anemia. The randomized, placebo-controlled study aims to assess safety and changes to hepcidin, iron, and key hematologic parameters.
Dr. Pablo Pergola will present the abstract titled "A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Non-Dialysis-Dependent Chronic Kidney Disease and Anemia" on Friday, October 25, 2024.
Disc Medicine (NASDAQ:IRON) has appointed Steve Caffé, MD as Chief Regulatory Officer. Dr. Caffé brings over 25 years of experience in global product development and regulatory affairs, with expertise in hematology, oncology, and rare diseases. He previously served as Head of Regulatory Affairs at CRISPR Therapeutics, contributing to the approval of Casgevy® for sickle cell disease and beta thalassemia.
Dr. Caffé's appointment comes at a important time for Disc Medicine as it transitions to a late-stage hematology company. His extensive experience, including contributions to over 40 new drug approvals worldwide, is expected to be valuable as Disc prepares for significant trial initiations across its portfolio in the coming year.
As part of his appointment, Dr. Caffé received an inducement equity award, including stock options and restricted stock units, subject to vesting conditions.
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company focusing on hematologic diseases, has announced its participation in four upcoming investor conferences in September 2024. The company's management will engage in fireside chats at the following events:
- 2024 Wells Fargo Securities Healthcare Conference (Sept. 6, 10:15 a.m. ET)
- Morgan Stanley 22nd Annual Global Healthcare Conference (Sept. 6, 1:05 p.m. ET)
- H.C. Wainwright 26th Annual Global Investment Conference (Sept. 11, 9:30 a.m. ET)
- 2024 Cantor Global Healthcare Conference (Sept. 19, 8:00 a.m. ET)
Live webcasts of these fireside chats will be accessible through Disc Medicine's investor relations website, with archived replays available after each event.
Disc Medicine (NASDAQ:IRON) reported Q2 2024 financial results and provided a business update. The company presented positive data for all three programs at the EHA 2024 Congress, demonstrating potential efficacy for bitopertin in EPP and DISC-0974 in anemia of myelofibrosis. Disc plans to provide updates on regulatory interactions for these programs in H2 2024. The company strengthened its financial position through a $178 million common stock offering, ending Q2 with $501 million in cash, expected to fund operations into 2027.
Financial highlights include R&D expenses of $23.5 million, up from $12.1 million in Q2 2023, and G&A expenses of $7.4 million, up from $5.2 million. The net loss for Q2 2024 was $26.4 million, compared to $15.9 million in Q2 2023. Disc Medicine continues to advance its portfolio, with upcoming milestones including regulatory discussions and data readouts in H2 2024.
Disc Medicine, a clinical-stage biopharmaceutical company (NASDAQ: IRON), announced an underwritten offering of 4,944,000 shares at $36 per share, expecting to raise approximately $178 million. The offering, closing on June 17, 2024, is led by Frazier Life Sciences and Logos Capital, with participation from significant institutional investors. Proceeds will fund ongoing and new clinical research, working capital, and other corporate purposes. Leerink Partners is the sole bookrunner.